Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 346

    1.

    I try to be a minimalist in laboratory testing.

    Cheson BD.

    Clin Adv Hematol Oncol. 2009 Aug;7(8):486. No abstract available. PMID: 19927974 [PubMed - in process]

    2.

    Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909.

    Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP.

    J Clin Oncol. 2009 Nov 16. [Epub ahead of print]PMID: 19917845 [PubMed - as supplied by publisher]Related articles

    3.

    Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.

    Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD.

    Cancer. 2009 Nov 4. [Epub ahead of print]PMID: 19890959 [PubMed - as supplied by publisher]Related articles

    4.

    Hematology: The case against rituximab maintenance.

    Cheson BD.

    Nat Rev Clin Oncol. 2009 Nov;6(11):622-4. No abstract available. PMID: 19861992 [PubMed - in process]Related articles

    5.

    Outcomes of patients with burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

    Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW.

    Clin Lymphoma Myeloma. 2009 Aug;9(4):307-10.PMID: 19717381 [PubMed - in process]Related articles

    6.

    Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia.

    Cheson BD, Cortés JE, Jagannath S.

    Clin Lymphoma Myeloma. 2009 Aug;9(4):266. No abstract available. PMID: 19717375 [PubMed - in process]Related articlesFree article

    7.

    The new and ever changing PhRMA guidelines are impeding productive relationship.

    Cheson BD.

    Clin Adv Hematol Oncol. 2009 Jun;7(6):350. No abstract available. PMID: 19645132 [PubMed - indexed for MEDLINE]Related articles

    8.

    Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.

    Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchal J, Peterson BA; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group.

    Leuk Lymphoma. 2009 Oct;50(10):1606-17.PMID: 19626540 [PubMed - in process]Related articles

    9.

    Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.

    Cheson BD.

    Clin Adv Hematol Oncol. 2009 Apr;7(4):263-71. Review.PMID: 19521331 [PubMed - indexed for MEDLINE]Related articles

    10.

    Resveratrol and cancer prevention.

    Cheson BD.

    Clin Adv Hematol Oncol. 2009 Mar;7(3):142. No abstract available. PMID: 19402261 [PubMed - indexed for MEDLINE]Related articles

    11.

    Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.

    Cheson BD.

    Curr Opin Hematol. 2009 Jul;16(4):299-305. Review.PMID: 19367159 [PubMed - indexed for MEDLINE]Related articles

    12.

    Adult Burkitt lymphoma: too soon to declare victory.

    Cheson BD.

    Oncology (Williston Park). 2008 Nov 30;22(13):1518-9. No abstract available. PMID: 19227573 [PubMed - indexed for MEDLINE]Related articles

    13.

    Bendamustine: rebirth of an old drug.

    Cheson BD, Rummel MJ.

    J Clin Oncol. 2009 Mar 20;27(9):1492-501. Epub 2009 Feb 17. Review. Erratum in: J Clin Oncol. 2009 Jun 10;27(17):2892. PMID: 19224851 [PubMed - indexed for MEDLINE]Related articles

    14.

    A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.

    Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G.

    Clin Cancer Res. 2008 Dec 15;14(24):8295-301.PMID: 19088047 [PubMed - indexed for MEDLINE]Related articles

    15.

    Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.

    Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, Devos S, Cheson BD, Damon LE, Said J.

    Leuk Lymphoma. 2008 Nov;49(11):2081-90.PMID: 19021050 [PubMed - indexed for MEDLINE]Related articles

    16.

    Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.

    Cheson BD.

    Clin Adv Hematol Oncol. 2008 Sep;6(9):4-6. No abstract available. PMID: 18998258 [PubMed - indexed for MEDLINE]Related articles

    17.

    Staging and evaluation of the patient with lymphoma.

    Cheson BD.

    Hematol Oncol Clin North Am. 2008 Oct;22(5):825-37, vii-viii. Review.PMID: 18954739 [PubMed - indexed for MEDLINE]Related articles

    18.

    Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

    O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD.

    Blood. 2009 Jan 8;113(2):299-305. Epub 2008 Oct 17.PMID: 18931344 [PubMed - indexed for MEDLINE]Related articles

    19.

    Bendamustine: a new therapeutic option for hematologic malignancies.

    Cheson BD.

    Clin Adv Hematol Oncol. 2008 Sep;6(9):631-3. No abstract available. PMID: 18827785 [PubMed - indexed for MEDLINE]Related articles

    20.

    Highlights of the 2008 International Conference on Malignant Lymphoma.

    Cheson BD.

    Clin Lymphoma Myeloma. 2008 Aug;8(4):205-8. No abstract available. PMID: 18765307 [PubMed - indexed for MEDLINE]Related articlesFree article

    21.

    Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.

    Cheson BD, Leonard JP.

    N Engl J Med. 2008 Aug 7;359(6):613-26. Review. No abstract available. PMID: 18687642 [PubMed - indexed for MEDLINE]Related articles

    22.

    Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

    Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD.

    J Clin Oncol. 2008 Sep 20;26(27):4473-9. Epub 2008 Jul 14.PMID: 18626004 [PubMed - indexed for MEDLINE]Related articles

    23.

    New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.

    Cheson BD.

    Radiol Clin North Am. 2008 Mar;46(2):213-23, vii.PMID: 18619377 [PubMed - indexed for MEDLINE]Related articles

    24.

    Recent developments in the treatment of CLL.

    Cheson BD.

    Clin Adv Hematol Oncol. 2008 May;6(5):6-8; quiz 10-2. No abstract available. PMID: 18578096 [PubMed - indexed for MEDLINE]Related articles

    25.

    New response criteria for lymphomas in clinical trials.

    Cheson BD.

    Ann Oncol. 2008 Jun;19 Suppl 4:iv35-8. Review. No abstract available. PMID: 18519399 [PubMed - indexed for MEDLINE]Related articlesFree article

    26.

    Most important accomplishments.

    Cheson BD.

    Clin Adv Hematol Oncol. 2008 Mar;6(3):150. No abstract available. PMID: 18496899 [PubMed - indexed for MEDLINE]Related articles

    27.

    Oblimersen for the treatment of patients with chronic lymphocytic leukemia.

    Cheson BD.

    Ther Clin Risk Manag. 2007 Oct;3(5):855-70.PMID: 18473009 [PubMed - in process]Related articlesFree article

    28.

    Implementing an expressive writing study in a cancer clinic.

    Morgan NP, Graves KD, Poggi EA, Cheson BD.

    Oncologist. 2008 Feb;13(2):196-204.PMID: 18326123 [PubMed - indexed for MEDLINE]Related articlesFree article

    29.

    Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

    Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD.

    Ann Oncol. 2008 May;19(5):964-9. Epub 2008 Feb 21.PMID: 18296419 [PubMed - indexed for MEDLINE]Related articlesFree article

    30.

    Lenalidomide for the treatment of B-cell malignancies.

    Chanan-Khan AA, Cheson BD.

    J Clin Oncol. 2008 Mar 20;26(9):1544-52. Epub 2008 Feb 19. Review.PMID: 18285605 [PubMed - indexed for MEDLINE]Related articles

    31.

    Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

    Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD; Cancer and Leukemia Group B.

    Br J Haematol. 2008 Feb;140(3):313-9.PMID: 18217897 [PubMed - indexed for MEDLINE]Related articles

    32.

    Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia.

    Blood. 2008 Jun 15;111(12):5446-56. Epub 2008 Jan 23. Erratum in: Blood. 2008 Dec 15;112(13):5259. PMID: 18216293 [PubMed - indexed for MEDLINE]Related articlesFree article

    33.

    Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

    Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD.

    J Clin Oncol. 2008 Jan 10;26(2):204-10. Erratum in: J Clin Oncol. 2008 Apr 10;26(11) 1911. PMID: 18182663 [PubMed - indexed for MEDLINE]Related articles

    34.

    Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

    Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS; American Society of Clinical Oncology.

    J Clin Oncol. 2008 Jan 10;26(2):313-25. Epub 2007 Dec 17. Erratum in: J Clin Oncol. 2008 Mar 10;26(8):1394. PMID: 18086794 [PubMed - indexed for MEDLINE]Related articles

    35.

    Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies.

    Cheson BD.

    Semin Oncol. 2007 Dec;34(6 Suppl 5):S3-7. Review.PMID: 18086345 [PubMed - indexed for MEDLINE]Related articles

    36.

    Emerging treatments for indolent lymphoma.

    Cheson BD, Gregory SA, Marcus R.

    Clin Adv Hematol Oncol. 2007 May;5(5 Suppl 8):1-9; quiz 11-2.PMID: 17637594 [PubMed - indexed for MEDLINE]Related articles

    37.

    The International Harmonization Project for response criteria in lymphoma clinical trials.

    Cheson BD.

    Hematol Oncol Clin North Am. 2007 Oct;21(5):841-54. Review.PMID: 17908623 [PubMed - indexed for MEDLINE]Related articles

    38.

    Although many of the items are natural products, we do not know what harm they might cause in the often excessive quantities that are recommended.

    Cheson BD.

    Clin Adv Hematol Oncol. 2007 Jul;5(7):499. No abstract available. PMID: 17722359 [PubMed - indexed for MEDLINE]Related articles

    39.

    The role of FDG-PET scans in patients with lymphoma.

    Seam P, Juweid ME, Cheson BD.

    Blood. 2007 Nov 15;110(10):3507-16. Epub 2007 Aug 20. Review.PMID: 17709603 [PubMed - indexed for MEDLINE]Related articlesFree article

    40.

    Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

    Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL.

    Leuk Lymphoma. 2007 Jul;48(7):1313-9.PMID: 17613759 [PubMed - indexed for MEDLINE]Related articles

    41.

    A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.

    Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A.

    Ann Oncol. 2007 Jul;18(7):1216-23. Epub 2007 Apr 29.PMID: 17470451 [PubMed - indexed for MEDLINE]Related articlesFree article

    42.

    Overcoming mechanisms of RECISTance in lymphoma.

    Cheson BD.

    Leuk Lymphoma. 2007 Mar;48(3):447-8. No abstract available. PMID: 17454580 [PubMed - indexed for MEDLINE]Related articles

    43.

    Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

    Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP; Cancer Leukemia Group B.

    Ann Oncol. 2007 Jun;18(6):1071-9. Epub 2007 Apr 10.PMID: 17426059 [PubMed - indexed for MEDLINE]Related articlesFree article

    44.

    Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.

    Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD; Cancer and Leukemia Group B.

    Leuk Lymphoma. 2007 Jan;48(1):97-103.PMID: 17325852 [PubMed - indexed for MEDLINE]Related articles

    45.

    Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

    Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD; Imaging Subcommittee of International Harmonization Project in Lymphoma.

    J Clin Oncol. 2007 Feb 10;25(5):571-8. Epub 2007 Jan 22.PMID: 17242397 [PubMed - indexed for MEDLINE]Related articles

    46.

    Revised response criteria for malignant lymphoma.

    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma.

    J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22.PMID: 17242396 [PubMed - indexed for MEDLINE]Related articles

    47.

    The gift that keeps on giving.

    Cheson BD.

    Clin Adv Hematol Oncol. 2006 Nov;4(11):787. No abstract available. PMID: 17193720 [PubMed - indexed for MEDLINE]Related articles

    48.

    Risky management.

    Cheson BD.

    Clin Adv Hematol Oncol. 2006 Jul;4(7):481. No abstract available. PMID: 17147233 [PubMed - indexed for MEDLINE]Related articles

    49.

    Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

    Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD; Cancer and Leukemia Group B Study 9153.

    Cancer. 2006 Dec 15;107(12):2817-25.PMID: 17120198 [PubMed - indexed for MEDLINE]Related articlesFree article

    50.

    Radioimmunotherapy of non-Hodgkin's lymphomas.

    Cheson BD.

    Curr Drug Targets. 2006 Oct;7(10):1293-300. Review.PMID: 17073591 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...